Health Care·Biotechnology·$109.4B
Vertex Pharmaceuticals (VRTX) is a biotechnology company focused on developing innovative therapies for serious diseases, particularly cystic fibrosis. With a market cap of $111 billion, it plays a significant role in the healthcare sector, addressing unmet medical needs and advancing treatment options.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Total revenue reflects the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
6Q
EPS Beat Rate
88%
Avg EPS Surprise
+16.54%
Avg Stock Reaction
+0.73%
In Q4-2025, Vertex reported an EPS of $5.03, exceeding expectations by 14.21%. The stock reacted positively, gaining 0.82% the following day.
Management Promises & Guidance
Analysts expect Vertex to continue its strong performance with an EPS of $4.29 and revenue of $3.0 billion. The company has a solid track record of beating earnings estimates.
Bull Case
If Vertex exceeds the EPS and revenue estimates, it could signal strong demand for its therapies and continued growth, potentially boosting investor confidence.
Bear Case
Conversely, if the company misses expectations or shows signs of slowing growth, it could raise concerns about its market position and lead to a negative stock reaction.
EPS
$4.29Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$3.0BTotal revenue reflects the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Vertex's EPS exceed the consensus estimate of $4.29?
A significant beat on EPS could indicate strong operational performance and boost investor confidence.
Q2
What is the revenue outlook for the next quarter, especially in light of recent product launches?
Understanding revenue growth will provide insight into market demand for Vertex's therapies and overall business health.
Why consensus could be wrong
The consensus may underestimate Vertex's growth potential due to its recent product innovations and market expansion strategies.
Supporting Evidence
Vertex has consistently beaten EPS estimates, indicating stronger-than-expected operational performance.
The options market is pricing a significant move, suggesting that investors anticipate volatility that may not align with consensus expectations.
Key Risk
If Vertex's revenue growth exceeds $3.2 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating Vertex's ability to maintain its growth trajectory amid increasing competition and market pressures.
Bull Confirmed If
An EPS of $4.50 or higher would confirm strong demand and operational efficiency.
Bear Confirmed If
An EPS below $4.00 would raise concerns about slowing growth and market competitiveness.
Implied Move
±4.88%
Historical Avg
±0.8%
The options market is pricing in a significant move around the earnings announcement, suggesting uncertainty or anticipation among investors.
Options are pricing ±4.9% while VRTX has averaged ±0.8% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Vertex beats expectations, history suggests a potential stock increase of around 0.54%, confirming strong market demand.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously as investors await further guidance.
Miss
A miss could lead to a stock decline, with historical data suggesting an average drop of around 2.03%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COLGATE PALMOLIVE CO
May 1, 2026